Compare Neurocrine Biosciences Inc (NBIX) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Petróleo Brasileiro SA — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B), while Petróleo Brasileiro SA trades at $24.63 (market cap $151.94B). The key difference: Petróleo Brasileiro SA is far larger — about 10.6× Neurocrine Biosciences Inc's market cap, and Petróleo Brasileiro SA pays a 6.79% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Petróleo Brasileiro SA for 25 Days on average.
| NBIX | PBR | |
|---|---|---|
Market Cap | $14.36B | $151.94B |
Volume | 1,237,180 | 30,240,092 |
Sector | Health | Energy |
52-Week High | $185.50 | $24.69 |
52-Week Low | $123.10 | $11.54 |
Typical Hold Time | 23 Days | 25 Days |
Enterprise Value | $14.37B | $212.36B |
Dividend Yield | — | 6.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Petrobras (PBR) trades at $23.99, up 0.8% today, with a bullish technical signal from moving averages and strong fundamental metrics including a P/E of 6.24 and net income margin of 24.52%. Recent news highlights a new oil discovery off Amapa and the deployment of the P-80 platform, supporting production growth. Cash flow from operations remains robust at $36.05 billion for 2025, though 2026 projections show a net cash outflow.
The outlook is positive given low valuations, high profitability, and strategic expansions, but risks include volatile oil prices and political influence in Brazil. Analysts are generally bullish with a 50% buy rating and a consensus price target of $22.33, slightly below the current price, indicating potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
